{
    "nctId": "NCT00580333",
    "briefTitle": "Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer",
    "officialTitle": "A Phase II Trial of Preoperative Cisplatin and Bevacizumab in Estrogen Receptor (ER) Negative, Progesterone (PR) Negative, Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 51,
    "primaryOutcomeMeasure": "Pathologic Complete Response Rate After Preoperative Therapy With Cisplatin and Bevacizumab in ER-, PR-, Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early Breast Cancer.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* All tumors must be ER-, PR- and HER2-negative\n* Clinical stage T2 or T3, N0-3, M0. Subjects with inflammatory breast cancer are not eligible\n* For subjects with clinically negative axilla, a sentinel lymph node biopsy will be performed either up front or after preoperative therapy at the discretion of the subject's physicians; for subjects with a clinically positive axilla, a needle aspiration or core biopsy will be performed to confirm the presence of metastatic disease in the lymph nodes.\n* 18 years of age or older\n* Performance status (PS) of 0 or 1\n* Use of an effective means of contraception in subjects of child-bearing potential\n* Normal organ function as described in the protocol\n\nExclusion Criteria:\n\n* Any prior cytotoxic chemotherapy or radiation for the current breast cancer\n* HER2-negative ipsilateral breast recurrence, unless prior treatment consisted of excision alone for ductal carcinoma in situ (DCIS)or breast-conserving treatment and hormonal therapy for DCIS or invasive cancer\n* Life expectancy of less than 12 weeks\n* Current, recent, or planned participation in an experimental durg study other than a Genentech-sponsored bevacizumab cancer study\n* Renal dysfunction for which exposure to cisplatin would require dose modifications\n* Steroid dependent asthma\n* Peripheral neuropathy of any etiology that exceeds grade 1\n* Uncontrolled diabetes\n* History of malignancy treated without curative intent\n* Any other pre-existing medical condition that would represent toxicity in excess of grade 1\n* Inadequately controlled hypertension\n* Any prior history of hypertensive crisis or hypertensive encephalopathy\n* New York Heart Association (NYHA) Grade II or greater congestive hear failure\n* History of myocardial infarction or unstable angina within 12 months prior to study enrollment\n* Any history of stroke or transient ischemic attack at any time\n* Known central nervous system (CNS) disease\n* Significant vascular disease\n* Symptomatic peripheral vascular disease\n* Evidence of bleeding diathesis or coagulopathy\n* Major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to study enrollment\n* History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to study enrollment\n* Serious, non-healing wound, ulcer or bone fracture\n* Proteinuria at screening\n* Known hypersensitivity to any component of bevacizumab\n* Pregnant or lactating",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}